Latest Conference Articles

HELIOS Phase 1 showed consistent reductions in retinal fluid with OTX-TKI, paving the way for pivotal HELIOS-2 and HELIOS-3 trials.

Gildeuretinol has also been evaluated in atrophic age-related macular degeneration, said Philip J. Ferrone, MD

The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim.

New research reveals subretinal drusenoid deposits in Black and Hispanic AMD patients may signal higher vascular disease risk

Optogenetics shows promise in improving mobility and object recognition for patients with retinitis pigmentosa and Stargardt disease.

During the American Academy of Ophthalmology annual scientific meeting, the organization shared breaking news and updates from ongoing projects.

Joel Schuman, MD, explore the latest advancements in glaucoma laser treatments, including innovative techniques like DSLT and the benefits of selective laser trabeculoplasty

Sunir J. Garg, MD, explores the nuances of endophthalmitis, distinguishing between infectious and non-infectious responses for effective patient management.

Research reveals significant vision improvements and extended treatment intervals with aflibercept 8 mg for age-related macular degeneration and diabetic edema patients.

Phase 2 STARLIGHT study participants, particularly those with the macular phenotype, experienced meaningful gains in visual acuity at 48 weeks.

Bedrood describes improved visualization of the ciliary body, efficient setup, and favorable postoperative outcomes.

The investigators noted that this report is the first about subretinal drusenoid deposits in Black and Hispanic patients with age-related macular degeneration.

Innovations in selective laser trabeculoplasty and laser cyclophotocoagulation focus on procedural efficiency, patient comfort, and evolving first-line treatment strategies.

The annual scientific meeting of the American Academy of Ophthalmology highlighted research in retina, refractive surgery, and accessible care.

John P. Berdahl, MD, discusses advanced lens options for patients with pseudoexfoliation, highlighting considerations for successful longterm outcomes.

Continued research shows that earlier treatment significantly enhances tissue preservation in patients with geographic atrophy, emphasizing the importance of timely intervention.

In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.

A study shows enhanced safety and efficacy in epi-on cross-linking for keratoconus, utilizing oxygen-rich boost goggles during treatment.

A new study reveals enhanced safety and efficacy in epi-on cross-linking for keratoconus, utilizing oxygen-rich boost goggles during treatment.

The second day of the annual scientific meeting of the American Academy of Ophthalmology highlighted advancements in AI, surgery technology, and money-saving solutions.

Data suggests the candidate can reduce the number of injections and treatment burden for patients

Dr. Singh reported that when technicians understand why they are performing a diagnostic test, they perform better and think critically in patient care situations.

The first day of the American Academy of Ophthalmology meeting in Orlando, Florida featured presentations centered on eye injuries and data insights.

Dr Khanani shared his first-time results talk during an AAO specialty day

The 18-month extension of the GATHER2 trial indicated continued benefit for patients receiving avacincaptad pegol, with efficacy gains increasing over time.